

Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)

NCT06907173

Status	RECRUITING
Phase	Phase 3
Sponsor	University of Virginia
Enrollment	770 participants

Key Eligibility Criteria

Inclusion (6)

- The patient was witnessed to have a convulsive seizure for greater than 5-minute duration
- The patient received an adequate dose of benzodiazepines. The doses may be divided.
- The last dose of a benzodiazepine was administered 5-30 minutes before study drug administration.
- Continued or recurring seizures in the Emergency Department.
- Age 1 years or older

... and 1 more (see full listing online)

Exclusion (12)

- Known pregnancy
- Prisoner
- Opt-out identification or otherwise known to be previously enrolled in KESETT
- Treatment with a second line anticonvulsant (FOS, PHT, VPA, LEV, phenobarbital, or other agents defined in the MoP) for this episode of SE
- Treatment with sedatives with anticonvulsant properties other than benzodiazepines for this episode of SE(propofol, etomidate, ketamine or other agents defined in the MoP)

... and 7 more (see full listing online)

Locations (31 total)

Arthur M. Blank Hospital, Georgia, Alabama, United States
Banner University Medical Center - Tucson Campus, Tucson, Arizona, United States
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
... and 28 more locations